
January 16 & 17, 2026 - Brussels
Two days packed with top expertise, debate, and insights from the past year in breast cancer care.
Institut Jules Bordet, Hôpital Universitaire de Bruxelles & UZ Leuven Hospital invite you to this annual double meeting, which has become a fixture.
On Friday evening, January 16, Belgian specialists will present their perspectives in the “Breast Cancer Debate of the Year 2025” – with lively discussions on current topics such as CDK4/6 inhibitors, radiotherapy in low-risk patients, and liquid biopsies.
On Saturday, January 17, the “Highlights of 2025 in Breast Cancer” will follow, where experts will present the latest research results and clinical developments.
An annual meeting for Belgian breast cancer experts to share knowledge and discuss the latest data in a clinical context.
Join us either in person at The Hotel or participate online from wherever you are.
📍The Hotel, Boulevard de Waterloo 38, 1000 Brussels
Institut Jules Bordet, Hôpital Universitaire de Bruxelles & UZ Leuven Hospital invite you to this annual double meeting, which has become a fixture.
On Friday evening, January 16, Belgian specialists will present their perspectives in the “Breast Cancer Debate of the Year 2025” – with lively discussions on current topics such as CDK4/6 inhibitors, radiotherapy in low-risk patients, and liquid biopsies.
On Saturday, January 17, the “Highlights of 2025 in Breast Cancer” will follow, where experts will present the latest research results and clinical developments.
An annual meeting for Belgian breast cancer experts to share knowledge and discuss the latest data in a clinical context.
Join us either in person at The Hotel or participate online from wherever you are.
📍The Hotel, Boulevard de Waterloo 38, 1000 Brussels
Chairs: Evandro de Azambuja (Institut Jules Bordet) & Hans Wildiers (Uz Leuven)
Breast Cancer Debate of the Year 2025
Friday 16th January 2026
18:00 > Reception and dinner
19:15 - 19:20 > Introduction by the chairs
Evandro de Azambuja & Hans Wildiers
19:20 - 19:55 > Do all patients with node-positive luminal breast cancer require adjuvant CDK4/6 inhibitors?
Case presantation: Luca Arecco (IJB-HUB)
Favour: E. Naert (UZ Gent)
Against: P. Neven (KUL)
Discussion: all
19:55 - 20:30 > Omission of radiotherapy in older women with low-risk breast cancer
Case presentation: L. vander veeken (UZ Leuven/ UCL)
Favour: P. Poortmans (ZAS/UZA)
Against: J. Verhoeven (UZ Leuven)
Discussion: all
20:30 - 20:50 > COFFEE BREAK
20:50 - 21:25 > Is liquid biopsy ready for prime use in patients with early and metastatic disease?
Case presentation: N. Honore (UCL)
Favour: L. Teuwen (UZA)
Against: P. Foidart (CHU Liège)
Discussion: all
21:25 - 21:40 > Second line therapy for HR+/HER2- metastatic breast cancer:
a critical review P. Aftimos (Inst Jules Bordet, HUB)
21:40 > Closing and take-home messages
Highlights of 2025 in Breast cancer
Saturday 17th January 2026
08:30 - 09:00 > Welcome Coffee
09:00 - 09:05 > Welcome and introduction by the chairs
Evandro de Azambuja & Hans Wildiers
09:05 - 09:50 > Translational research data
F. Duhoux (UCL)
09:50 - 10:15 > What's new in breast radiation
A. De Caluwé (AZSM & IJB & HUB)
10:15 - 10:40 > What's new in breast surgery
M. Vanhoeij (UZ Brussels)
10:40 - 11:00 > COFFEE BREAK
11:00 - 11:35 > Early breast cancer: systemic therapies
M. Piccart (Inst. Jules Bordet, HUB)
11:35 - 12:10 > Metastatic breast cancer: systemic therapies
D. Taylor (CHU Namur)
12:10 - 12:30 > Q&A and take-home messages
12:30 > Closing
Policy Pages
Copyright AccrediMix © 2026
AccrediMix VZW
Beekboshoek 202, 2550 Kontich
VAT: BE 1013.610.012
IBAN: BE40 7350 6931 4063 - BIC: KREDBEBB
Beekboshoek 202, 2550 Kontich
VAT: BE 1013.610.012
IBAN: BE40 7350 6931 4063 - BIC: KREDBEBB
